ERYTECH PHARMA (0QSS) Stock Statistics & Valuation Metrics

ERYTECH PHARMA has a market cap or net worth of €3.12M. The enterprise value is ―.

ERYTECH PHARMA has 10,050,675 shares outstanding. The number of shares has decreased by -2.65% in one year.

ERYTECH PHARMA’s return on equity (ROE) is -0.92 and return on invested capital (ROIC) is -56.27%.

The current PE Ratio of ERYTECH PHARMA is -0.85. ERYTECH PHARMA’s PEG ratio is >-0.01.

In the last 12 months, ERYTECH PHARMA had revenue of 1.33M and earned -23.49M in profits. Earnings per share was -5.00.

In the last 12 months, operating cash flow was -20.89M and capital expenditures -601.00K, giving a free cash flow of -21.49M billion.

ERYTECH PHARMA pays an annual dividend of ―, resulting in a dividend yield of ―

ERYTECH PHARMA upcoming earnings date is May 14, 2025, TBA Not Confirmed.

ERYTECH PHARMA as a current ratio of 1.06, with Debt / Equity ratio of 70.34%

In the past 12 months, ERYTECH PHARMA has paid -1.25M in taxes.

ERYTECH PHARMA EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -0.92.

ERYTECH PHARMA has €1.46M in cash and marketable securities with €0.00 in debt, giving a net cash position of €9.41M billion.

Gross margin is 78.09%, with operating margin of -1784.31%, and net profit margin of -1771.34%.

The average price target for ERYTECH PHARMA is ―, which is 11.43% higher than the current price. The consensus rating is ―